Knopp Biosciences Changing the Course of Human Health

Michael E. Bozik, M.D.

PRESIDENT AND CHIEF EXECUTIVE OFFICER

Prior to joining Knopp, Dr. Bozik served as VP global R&D for Bayer Healthcare, Consumer Care Division. Previously he served Bristol-Myers Squibb Co. as VP of neuroscience clinical. At BMS he was also VP of R&D and business operations in consumer medicines and specialty pharmaceuticals. Earlier in his career he directed the Brain Tumor Center at the University of Pittsburgh Cancer Institute and served as chief of the Division of Neuro-Oncology. He completed his B.A. from Notre Dame, his M.D. from the University of Pittsburgh, and his residency and fellowship training in neurology and neuro-oncology at the University of Michigan and Pitt. He is a director of Life Sciences PA and a recipient of the Ernst & Young Entrepreneur of the Year Award.

Mark Kreston

CHIEF COMMERCIAL OFFICER

Mr. Kreston brings 30 years of drug commercialization experience to Knopp, most recently at Celgene, where he served as Corporate VP of Global Marketing, Inflammation & Immunology. Previously he served at Johnson & Johnson as Worldwide VP Global Marketing, Immunology. Earlier, at Bristol-Myers Squibb, he was Worldwide VP Global Marketing, Immunology, and served as President of Consumer Medicines. His record of major pharmaceutical product launches includes Otezla for psoriasis and Orencia for rheumatoid arthritis. He is a graduate of the University of Pennsylvania and the Cornell Johnson Graduate School of Management.

Gregory T. Hebrank, M.D., MBA

EVP, CORPORATE OPERATIONS & FINANCE

Dr. Hebrank, a co-founder of Knopp, is a successful longtime investor in public and private biotech equities and was the co-founder of and a partner in a successful clinical obstetrics and gynecologic practice in Westmoreland County, Pennsylvania. He earned a B.S. in Biomedical Engineering from Vanderbilt University, an M.D. from Tulane University School of Medicine, and completed his residency training in obstetrics and gynecology at Magee-Women’s Hospital. He completed his M.B.A. at Carnegie Mellon University’s Tepper School of Business. He serves on the board of LaunchCyte LLC.

Steven Dworetzky, Ph.D.

CHIEF SCIENTIFIC OFFICER

Previous to joining Knopp in 2007, Dr. Dworetzky was a senior principal research investigator for the neuroscience group at Bristol-Myers Squibb, with an emphasis on ion channel modulation. During his tenure, Dr. Dworetzky’s research yielded seven issued U.S. patents for which he is an inventor and has authored more than 40 peer-reviewed publications. He holds a B.A. in biology and chemistry from Skidmore College and a Ph.D. in cell biology from the University of Florida and was an adjunct assistant professor of molecular physiology at Yale University.

Calman Prussin, M.D.

VICE PRESIDENT, CLINICAL AND TRANSLATIONAL RESEARCH

Dr. Prussin comes to Knopp from the National Institute of Allergy and Infectious Diseases (NIAID), where he was a principal investigator in numerous clinical trials in eosinophil-associated diseases. He served on the FDA Pulmonary-Allergy Drugs Advisory Committee and is the author of 100 peer-reviewed publications. He is a past chair of the American Board of Allergy and Immunology and a Fellow of the American Academy of Allergy and Immunology. He received his B.A. in chemistry at the University of California, San Diego; his M.D. from the USC Keck School of Medicine, and his training in internal medicine at Los Angeles County-USC Medical Center. He has been the recipient of numerous awards and service medals from the U.S. Public Health Service, from which he retired with the rank of Captain.

Jim Mather

VICE PRESIDENT, CLINICAL OPERATIONS AND DATA MANAGEMENT

Jim Mather has 30 years’ experience in clinical research and development as a Phase 1 clinical operations manager, director of study operations for Phase 2-4 clinical trials, supervisor of data management and biostatistics, and vendor management. He developed and conducted studies for both small and mid-sized biotech pharma, as well as for a top five large pharma company during his time as a CRO clinical operations group lead.

Rachel Kopper

DIRECTOR, BUSINESS OPERATIONS AND FINANCE

A Knopp employee since 2007, Ms. Kopper also currently serves as National President-Emeritus and Board Chair of Women in Bio, an organization of more than 2,500 professionals committed to promoting careers, leadership, and entrepreneurship for women in the life sciences. Previously she was instrumental in establishing the Pittsburgh chapter of WIB. Earlier in her career she served as a project manager for The Forum Corporation and served as a forestry extension volunteer for the United States Peace Corps. She holds an MBA from Chatham University and is a graduate of Westminster College.

Thomas Petzinger Jr.

EVP, BUSINESS DEVELOPMENT & PUBLIC AFFAIRS

Mr. Petzinger is a founder of LaunchCyte LLC, a life sciences incubator that co-founded Knopp. He also serves as a director of other LaunchCyte companies, including Immunetrics Inc., Crystalplex Corp., Reaction Biology Corp., and Celsense Inc. Prior to co-founding LaunchCyte, he spent 22 years at The Wall Street Journal, where he served as Washington economics editor, deputy Washington bureau chief, millennium editor, and weekly columnist. He has also written three business books, two selected as notable books of the year by The New York Times. He received his B.S. in Journalism from Northwestern University.

Benjamin A. Gomez

MANAGING DIRECTOR OF PILOT HOUSE ASSOCIATES, LLC

Mr. Gomez serves as Managing Director of Pilot House Associates, a family investment office in Boston. He joined Pilot House in 1998 as Treasurer. Prior to joining Pilot House, Mr. Gomez held various positions at Continental Cablevision and the Bank of New York. He received a bachelor's degree in Foreign Service, with honors, from Georgetown University and an MBA from Columbia University's Graduate School of Business.

Jeffrey S. McCormick

CHAIR AND MANAGING GENERAL PARTNER OF SATURN CAPITAL

Mr. McCormick is the Chairman and Managing General Partner of Saturn. He founded Saturn in 1993, focusing on energy, electronic commerce, specialty materials, and select opportunistic investments. He then led the expansion of Saturn with the launch of both Saturn Partners Limited Partnership I and II. Mr. McCormick has over 20 years of experience as an investment banker, entrepreneur and venture capitalist. Prior to founding Saturn, he worked as an analyst and investment banker with Bariston Associates, Boston. Mr. McCormick is a graduate of Syracuse University, where he received an MBA in Finance and a B.S. in biology.

Stephen E. Butts

CO-FOUNDER AND CEO OF ARRIVO BIOVENTURES, LLC

Mr. Butts is the co-founder and CEO of Arrivo BioVentures, LLC, a drug development company located in North Carolina. Previously he served as the CEO of Velo Bio, a clinical-stage company with a product for preeclampsia acquired by AMAG Pharmaceuticals in 2018. Prior to Velo, he was co-founder, President, and COO of Aerial BioPharma LLC, a drug development company that sold its lead drug for narcolepsy to Jazz Pharmaceuticals in 2014. Early in his career, Mr. Butts served as VP of Sales & Marketing at BioBehavioral Diagnostics Company, as well in assignments at Eli Lilly and Braintree Laboratories. He holds a BS degree in Business Administration and an MBA from the Kenan-Flagler School of Business at UNC-Chapel Hill.

C. David Adair, M.D.

CO-FOUNDER OF SOLAS BIOVENTURES

Dr. Adair was a founding member in 2014 of Solas BioVentures, which invests in life-changing therapeutics and medical device companies. He is Board certified in maternal-fetal medicine, obstetrics and gynecology, and hypertension, with special expertise in critical care, and recently retired as Professor and Vice Chair of Obstetrics and Gynecology at the University of Tennessee College of Medicine. Dr. Adair earned his medical degree from the Joan C. Edwards College of Medicine at Marshall University and completed his residency at the University of Florida Health Science Center and his fellowship training at Wake Forest University. He holds an MBA from the University of Tennessee Chattanooga.

Michael E. Bozik, M.D.

Gregory T. Hebrank, M.D., MBA

Thomas Petzinger Jr.